NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP).
The investigation concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
On September 25, 2025, the investment bank/brokerage firm, Jefferies Financial Group Inc. downgraded Medpace, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
On this news, Medpace's stock price fell $35.24 per share, or 9.9%, to close at $320.58 per share on September 25, 2024.
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.